Year: 2020

                                                                                                                                                           Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopeniaPhase 3 trial initiated to evaluate rilzabrutinib, the potential first BTK inhibitor (Bruton’s tyrosine kinase inhibitor) for the treatment of immune thrombocytopeniaRilzabrutinib previously granted FDA orphan drug designationPARIS – November 18, 2020 – The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the oral investigational Bruton’s tyrosine kinase (BTK) inhibitor, rilzabrutinib, which has the potential to be the first BTK inhibitor for the treatment of immune thrombocytopenia (ITP). In addition, following positive Phase 1/2 study results, a Phase 3 study...

                                                                                                                                                            La FDA accorde une procédure accélérée au rilzabrutinib pour le traitement de la thrombocytopénie immuneLancement d’un essai de phase III évaluant le rilzabrutinib, premier inhibiteur potentiel de la BTK (tyrosine kinase de Bruton) pour le traitement de la thrombocytopénie immune.Le rilzabrutinib a déjà obtenu le statut de médicament orphelin de la FDA.PARIS –  Le 18 novembre 2020 – La Food and Drug Administration (FDA) des États-Unis a accordé une procédure accélérée (Fast Track Designation) au rilzabrutinib, un inhibiteur expérimental de la tyrosine kinase de Bruton (BTK) par voie orale, qui a le potentiel de devenir le premier inhibiteur de la BTK pour le traitement de la thrombocytopénie...

Press ReleaseNokia, Elisa and Qualcomm achieve 5G speed record in FinlandCombined speeds from two devices hit 8 Gbps on a commercial 5G network on mmWave spectrumSupports low-latency, high-bandwidth services such as high-speed video downloads and VR/AR17 November 2020Espoo, Finland – Nokia, Elisa and Qualcomm Technologies, Inc. today announced that they have achieved the world’s fastest 5G speeds on a commercial network in Finland by delivering 8 Gbps for the first time serving two 5G mmWave devices connected simultaneously. The fast speed, which was showcased at Elisa’s flagship store in Helsinki, Finland, will support a range of new low-latency, high-bandwidth services, such as high-speed video downloads, mission-critical or virtual reality (VR) and augmented reality (AR) applications. The service is expected to be implemented in 2021.The...

                                                                                                                                                            FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe diseaseThe FDA decision date for avalglucosidase alfa, an investigational enzyme replacement therapy, is set for May 18, 2021Regulatory submission based on positive data from two trials in patients with late-onset and infantile-onset Pompe disease, respectivelyAvalglucosidase alfa received FDA Breakthrough Therapy and Fast Track designations for the treatment of people with Pompe DiseasePompe disease, a rare degenerative muscle disorder, affects approximately 3,500 people in the U.S.Milestone reinforces 20+year commitment to Pompe disease communityPARIS – November 18, 2020 – The U.S. Food and...

                                                                                                                                                            La FDA accorde un examen prioritaire à l’avalglucosidase alpha, nouveau traitement potentiel de la maladie de Pompe  La FDA devrait rendre sa décision au sujet de l’avalglucosidase alpha, une enzymothérapie substitutive expérimentale, le 18 mai 2021La soumission réglementaire repose sur les données positives de deux essais menés chez des patients porteurs respectivement de la forme tardive et de la forme infantile de la maladie de Pompe.L’avalglucosidase alpha a obtenu le statut de traitement innovant (Breakthrough Therapy) de la FDA, de même qu’un examen accéléré (Fast Track) pour le traitement de la maladie de Pompe.La maladie de Pompe, une maladie musculaire dégénérative rare, affecte...

Moses Lake, WA, November 18, 2020: Reference is made to the announcement from REC Silicon ASA (the “Company”) of 20 December 2019. As set out therein, the Company received in December 2019 a claim of NOK 150 million (the “Claim”) from Nordea under an indemnification loan from Nordea related to the bankruptcy of a former subsidiary in 2012. The relevant bankruptcy estates have not yet been concluded. Nordea’s Claim is based on an assumption from Nordea that its loss will exceed said amount when the estates are concluded.REC Silicon has now received a writ of summons (no: “stevning”) which Nordea has taken out before the Asker and Bærum District Court, for payment of the Claim.The status of the Claim, including whether or not it may be time-barred in whole or in part, continues to be subject to...

VANCOUVER, British Columbia, Nov. 18, 2020 (GLOBE NEWSWIRE) — Clean Power Capital Corp. (CSE: MOVE)(FWB: 2K6A)(OTC: MOTNF) (“Clean Power” or the “Company” or “MOVE“). The Company’s 90 percent owned subsidiary PowerTap Hydrogen Fueling Corp. (“PowerTap”) is pleased to announce that it has partnered with Cryotek (cryotek.com) pursuant to an 8-month contract to provide engineering and design for the next generation PowerTap hydrogen filling stations, which is planned to be deployed across North America starting in 2021. The engineering design will include:Next Generation PowerTap Onsite Steam Methane Reformer (“SMR”) solution capable of producing 1,000kg+ per day;Gaseous and Liquid Hydrogen storage solutions capable of 1,000kg+ or more per day;CO2 capture solutions;Advanced hydrogen dispensing unit; andArtist rendition...

SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 7,258,065 shares of common stock of the Company, at a price to the public of $3.10 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about November 20, 2020, subject to satisfaction of customary closing conditions.H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.The Company also has granted to the underwriter a 30-day option to purchase up to an additional 1,088,709 shares of common stock...

VANCOUVER, British Columbia, Nov. 17, 2020 (GLOBE NEWSWIRE) — Patagonia Gold Corp. (“Patagonia” or the “Company”) (TSXV: PGDC) announces it has entered into an agreement with Cantomi Uruguay S.A. (“Cantomi”) to extend the maturity of the Cantomi Loan (as defined below) to December 31, 2022. Cantomi provided a US$15 million loan facility at 5% interest per annum (the “Cantomi Loan”), which was to mature on March 31, 2021. Other than the extension of the maturity date to December 31, 2022, all other terms of the Cantomi Loan remain unchanged. The Company also agreed to extend the maturity date of its bank indebtedness, being its operating lines of credit, from January 31, 2021 to December 31, 2021. Other than the extension of the maturity date to December 31, 2021, all other terms of the operating lines of credit will remain unchanged.Patagonia...

MADISON, Wis., Nov. 17, 2020 (GLOBE NEWSWIRE) — Alliant Energy Finance, LLC (“AEF”), a wholly-owned subsidiary of Alliant Energy Corporation (the “Company”) (NASDAQ:LNT) announced the pricing of a private offering of $200 million aggregate principal amount of 1.400% senior unsecured notes. The notes will be due on March 15, 2026. The closing of the offering is expected to occur on November 20, 2020, subject to customary closing conditions. The Company will fully and unconditionally guarantee the notes on a senior unsecured basis.The net proceeds from this offering are intended to be used to reduce the Company’s outstanding commercial paper and for general corporate purposes.The notes will be offered and sold to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”),...